Hart C. Anthony, Shears Paul. Color Atlas of Medical Microbiology.pdf

(EIA) 128 –129

Archaea 5

HIV antibody detection

killing of 35

453

Archaeopsylla erinacei 618

immunofluorescence

Arenaviruses 383,

125–128

462 –464

direct 125 –126, 127

clinical picture 463

indirect 127–128

diagnosis 464, 644, 645,

immunoprecipitation in

650

liquids and gels

epidemiology 464

121–123

pathogenesis 463

double diffusion tech-

pathogens 463

nique 121–122, 141

prevention 464

immunoelectropho-

Artemether 533, 534

resis 122 –123, 124

Artemisinin 533

immunoprecipitate

Artesunates 533

121

Arthritis

nephelometry 122

Lyme disease 326, 327

radial immunodiffu-

polyarthritis 115

sion technique 122,

septic 654

123

Arthropods 7, 606–607

Western blotting 123,

classification 606

125

zoonoses 29, 30

leptospirosis 329 –330

see also specific parasites

malaria 531

Arthrospores 351

radioimmunoassay (RIA)

Arthus reaction 114

128–129

Arylaminoalcohols 533

syphilis 321–322

Ascaridida 545

antilipoidal antibodies

Ascaris lumbricoides (as-

321–322

cariosis) 544, 577–579

antitreponema anti-

clinical manifestations

bodies 322

578 –579

Antibody-dependent cel-

control 579

lular cytotoxicity (ADCC)

diagnosis 579, 626, 634,

85, 139

640

Anticodon 179

epidemiology 578

Antigen assays 121 –129,

life cycle 577, 578

217, 409

morphology 577

agglutination reaction

occurrence 577

123–125

pathogenesis 578–579

amebosis 506

intestinal phase 579

complement fixation

larval migration

test (CFT) 125

578 –579

coproantigen detection

therapy 579

506, 622

Ascospores 352

enzyme immunoassay

Aseptic measures 35

(EIA) 128 –129

Aspergilloma 365

fungal infections 356

Aspergillus (aspergillosis)

HIV antigen detection

354, 364–366, 372

453

cerebral 365

immunofluorescence

clinical pictures 365

125–128

culture 364

direct 125 –126, 127

diagnosis 365

indirect 127–128

cardiovascular system

immunoprecipitation in

647

liquids and gels

cutaneous infection

121–123

652

double diffusion tech-

ear infection 658

nique 121–122, 141

eye infections 656, 657

nervous system 645,

chemical characteris-

646

tics 215

respiratory tract 633,

diagnostic animal

634

tests 217

flavus 364

molecular methods

fumigatus 354, 364, 365

216–217

morphology 364

morphological char-

pathogenesis 364

acteristics 214, 215

respiratory tract infec-

physiological charac-

tion 365

teristics 214, 215

therapy 366

see also Laboratory

Asthma 353

diagnosis

Astigmata 606, 612

invasion and spread 12

Astroviruses 383, 438,

killing of

439

kinetics 35–36

clinical picture 439

phagocytosis 23

diagnosis 439, 638

metabolism 160 –164

epidemiology 439

anabolic reactions 163

pathogenesis 439

catabolic reactions

Athlete’s foot 374

161–163

Atopia 109, 139

metabolic regulation

Atovaquone 533, 534, 535

164

Attachment pili 158

types of 160– 161

Autoantibody responses

molecular genetics

110–111

166–170

Autoimmune disease 113

morphology 146 –148

see also Immunopathol-

nomenclature 228

ogy

normal flora 24–25

Autoimmunity 43 –44,

nosocomial infections

110–111

343, 344

mechanisms 111

pathogenicity 7– 11

Autologous 139

genetics of 20–21

Autosomes 139

problem bacteria 24, 201

Avidity 139

spores 159 –160

Axostylata 477

taxonomy 218 –219

Azithromycin 191

toxins 15, 16–17

Azlocillin 193

typing 186

Azoles 356

virulence 7–11

Aztreonam 192

regulation of 18–20

zoonoses 28, 29

&B

see also specific bacteria

Bacterial culture 164,

212–214

B cells 45 –46, 67–71

bacterial mass 166

antigen presentation 63

cell count 165 –166

antigen recognition 52

conditions required for

clonal selection theory

growth 214

67

growth curve 165

interactions 72–75

nutrient media 164, 212,

maturation 47

213

memory 94–96

proliferation forms

proliferation 69–69

212–214

T-independent re-

see also specific bacteria

sponses 69 –71

Bacterial peliosis hepatis/

tolerance 93–94

splenica 334

B-cell attractant (BCA-1)

Bactericidal activity 196

83

Bacteriophages 175,

B-cell lymphoma 69

182 –186

burst size 185

resistance mechanisms

classification 326

composition 183

202

culture 326

definition 182

Biguanides 533

diagnosis 327, 645,

importance of 186

Bilharziosis see Schistoso-

651

latency period 185

ma (schistosomosis)

morphology 326

lysogeny 186

Bioburden 35

pathogenesis

morphology 182 –183

Biofilm 158 –159, 234

326 –327

release from host cell

Biopsies 624

see also Lyme disease

185

Bipolaris spp. 354, 369

clinical picture 325

reproduction 184–185

BK virus 415–416

culture 325

Bacteriostasis 196

clinical picture 415–416

diagnosis 325, 649

Bacteroidaceae 24, 225,

diagnosis 416

duttonii 226, 324–326,

317–319

pathogenesis 415–416

649

classification 317

Blastocystis hominis

epidemiology 325 –326

clinical pictures 318

504–505

garinii 226

culture 317

diagnosis 639

hermsii 226, 324–326

diagnosis 318

Blastomyces

morphology 324

epidemiology 319

brasiliensis 361

pathogenesis 325

morphology 317

dermatitidis 354, 361

prevention 325 –326

occurrence 317

diagnosis 657

recurrentis 226,

pathogenesis 317–318

Blastomycoses

324–326, 613, 649

prevention 319

North American 354,

relapsing fevers

therapy 318

361

324–326

Bacteroides spp. 225, 317,

diagnosis 361

significance 324

319

therapy 361

taxonomy 324

Balamuthia (balamuthio-

South American 354,

therapy 325

sis) 507

361

Botulinum neurotoxin 250

mandrillaris 507

diagnosis 361

Botulism 246, 250

Balantidium coli (balanti-

therapy 361

clinical picture 250

dosis) 542

see also Blastomyces

diagnosis 250, 646

Bang’s disease see Brucella

Blastospores 351

epidemiology 250

(brucellosis)

Blood flukes see Schistoso-

infant botulism 250

Bartonella 227, 334–335

ma

prevention 250

bacilliformis 227, 334

Blood sampling 210, 622

therapy 250

diagnosis 649

Boeck’s sarcoid, diagnostic

wound botulism 250

claridgeia 227, 334, 649

test 99

see also Clostridium bo-

classification 334

Bone infections 653 –654

tulinum

clinical pictures 334

Bone marrow 62

Brachycera 606, 616–617

culture 334

B cell maturation 47

bite reactions 616

diagnosis 335

dendritic cells 62

myiasis 617

epidemiology 335

transplantation 116

role as vectors 616

henselae 227, 334, 649

Bordetella 313, 315–316

Brazilian purpuric fever

morphology 334

bronchiseptica 315

303

quintana 227, 334, 613

parapertussis 315

Brill-Zinseer disease 332

therapy 335

pertussis 225, 313, 315

BRO penicillinases 278

Basal body 158

culture 315

Bronchiolitis 467, 632

Basidiospores 352

diagnosis 316, 632

Bronchitis 632

BCG vaccine 268

morphology 315

Bronchoalveolar lavage

Beard ringworm 374

pathogenesis 315

(BAL) 209

Bedbug 616

virulence regulation

Bronchopneumonia 240

Bence-Jones proteins 69,

19, 315

Bronchus-associated lym-

139

see also Whooping

phoid tissue (BALT) 48

Benzyl penicillin 193

cough

Brucella (brucellosis) 28,

Betalactam antibiotics 187,

Bornholm disease 653

225, 313–314

189 –193

Borrelia 324–328

abortus 225, 313, 648

chemical structures 195

afzelii 226

canis 225

mechanisms of action

burgdorferi 28, 226, 324,

classification 313

198, 199

326 –328

clinical picture 314

Clostridium C 669

Cell division 150

Chemoprophylaxis

therapy 299

Cell membrane see Cyto-

206–207, 402

transmission 299

plasmic membrane

see also specific infections

see also Vibrio cholerae

Cell wall 18, 152 –157

Chickenpox 422

Cholera toxin 16, 297–298

gram-negative bacteria

diagnosis 650

mechanism of action

154 –157

see also Varicella-zoster

298

gram-positive bacteria

virus (VZV)

Chromium release assay

152 –154

Chikungunya virus 441

134

tuberculosis bacteria

Chimeras 140

Chromoblastomycosis 355,

264

Chinese liver fluke

372

Cellulitis see Anaerobic

557–558

Chromomycosis 372

cellulitis

Chlamydia

diagnosis 652

Cephalosporins 189–190,

pneumoniae 227, 335,

Chromosomes 167, 179

195

339–340

Chronic obstructive pul-

group 1 189

diagnosis 632, 633

monary disease (COPD)

group 2 190

psittaci 227, 335,

632

group 3a 190

337–338

Ciliophora 477

group 3b 190

diagnosis 337–338,

Cimex lectularius 616

oral 190

633

Ciprofloxacin 189, 195

Cephalothin 189

epidemiology 338

Cistron 179

Ceratophyllidae 618–619

pathogenesis 337

Citrobacter 223, 280

clinical manifestations

therapy 338

amalonaticus 295

619

trachomatis 227,

freundii 295

control 619

335– 336

Cladosporium carrionii 355

diagnosis 619

clinical pictures

Clarithromycin 191

epidemiology 619

338–339

Clavulanic acid 192, 195

life cycle 618–619

diagnosis

Clindamycin 191, 195

morphology 618

cardiovascular sys-

CLIP (class II-inhibiting

Ceratophyllus gallinae 618

tem 647

protein) 140

Cercarial dermatitis 553

eye infections 655,

Clonal selection theory 67

Cerebral abscess 646

656, 657

Clone 180

Cerebral schistosomosis

urogenital tract 635,

Cloning 178 –179

553

636, 637

Clonorchis (clonorchiosis)

Cerebrospinal fluid sam-

Chlamydiae 5, 227–228,

544, 557–558

ples 210, 623

335– 337

clinical manifestations

Cervicitis 338, 636

classification 336

558

Cestoda 545, 560, 561

culture 337

diagnosis 558, 641, 643

diagnosis 640, 643

definition 336

epidemiology 558

see also specific parasites

morphology 148, 336

life cycle 558

Chagas disease 483,

elementary bodies

occurrence 557

491– 492, 616

336

prevention 558

clinical manifestations

initial bodies 336

sinensis 557

492

reproductive cycle 337

therapy 558

diagnosis 492, 625

see also Chlamydia

Clostridial myonecrosis see

epidemiology 491–492

Chloramphenicol 190

Gas gangrene

occurrence 491

mechanism of action 198

Clostridium 220 –221,

prevention 492

resistance mechanism

246–248, 651, 653, 654

therapy 492

202

botulinum 221, 250 –251

see also Trypanosoma

Chlorine 39 –40

diagnosis 250, 646

cruzi

Chloroquine 533, 534, 535

pathogenesis and 250

Chagoma 492

Cholangitis 641

toxin 250

Chancre

Cholecystitis 641

see also Botulism

hard 321

Cholera 296, 297–300

culture 246

trypanosome 489

clinical picture 299

difficile 221, 251

Chemokines 82 –83,

diagnosis 299, 639

diagnosis 251, 638

84–85, 139

epidemiology 299

morphology 246

constitutive 83, 84

prevention 299 –300

occurrence 246

inflammatory 84

source of infection 299

pathogens 246

perfringens 221

alternative activation 87,

ulcerans 261

diagnosis 638, 653

88 –89, 139

xerosis 261

toxin 16

classic activation 86,

Cotrimoxazole 194

tetani 220, 248–250

87,88

Cowpox 428

diagnosis 248, 646

control proteins 89

Coxiella burnetii 28, 227,

epidemiology 249

resistance to 13

330, 332

pathogenesis 248

Complementation 391

diagnosis 633

prophylaxis 249–250

Concanavalin A 140

transmission 28, 331

therapy 248

Condylomata acuminata

see also Q fever

toxin 16, 248

414

Coxsackievirus

see also Tetanus

Conidia 351

clinical syndromes 436

Cloxacillin 193

Conjugation 171, 175 –177,

diagnosis 630, 653

Clumping factor test 233

180

group A 435, 436

Cobra venom factor 140

Conjugation pili 158, 181

group B 436

Cocci 149

Conjunctivitis 303

Creeping eruption 617

Coccidea 477

diagnosis 655

diagnosis 652

Coccidioides immitis (coc-

inclusion 336, 339

see also Cutaneous larva

cidioidomycosis) 354, 360

swimming-pool 336,

migrans (CLM)

clinical picture 360

339

Creutzfeldt-Jakob disease

culture 360

viral 416

(CJD) 342, 473–474

diagnosis 360, 633,

Connatal listeriosis 253

epidemiology 474

644

Connective tissue infec-

new variant (nvCJD) 473,

epidemiology 360

tions 650 –653

474

morphology 360

see also specific infections

Croup 631

pathogenesis 360

Contamination 10

Cryoglobulin 140

therapy 360

Contracecum 604

Cryptococcus neoformans

Code 179

Coombs test 124–125

(cryptococcosis) 354,

Codon 179

Coproantigen detection

366–367

Colistin 194

506, 622

clinical picture 366–367

Colitis

Coproscopic diagnosis 503

culture 366

antibiotic-associated

Corepressor 179

diagnosis 366

251

Coronaviruses 383,

cardiovascular system

chronic 503

446 –448

647

hemorrhagic 294

clinical picture 447

nervous system 644,

pseudomembranous

diagnosis 446, 447

645

246, 251

gastrointestinal tract

respiratory tract 633

clinical course 251

638

epidemiology 367

diagnosis 251, 638

respiratory tract 630,

morphology 366

Colonization 10

634

pathogenesis 366–367

resistance 24–25

epidemiology 447–448

pulmonary cryptococ-

Colonizing factors (CFA)

pathogenesis 447

cosis 367

293

pathogens 446

therapy 367

Colorado tick fever 456

replication 447

Cryptosporidium (cryptos-

Coltiviruses 456

Corynebacterium

poridiosis) 517–520

Combination therapy

diphtheriae 221,

baileyi 517

205 –206

255 –258

canis 517

Combining site 140

culture 255 –256

clinical manifestations

Commensals 9, 24–25

diagnosis 256–257,

518–519

Common cold (rhinitis)

631

immunocompetent

438, 447, 630

epidemiology

persons 518

Common sheep tick

257–258

immunodeficient per-

607– 610

morphology 255

sons 518–519

Community-acquired

pathogenesis 256

diagnosis 504–505, 519,

pneumonia 633

toxin 16, 256

625, 639

Complement fixation test

see also Diphtheria

stool specimen hand-

(CFT) 125

jeikeium 261

ling 621

Complement system

pseudodiphtheriticum

epidemiology 518

86 –90, 140

261

transmission 29, 518

culture 373

immitis 605

Duffy antigen receptor for

diagnosis 652

repens 605

chemokines (DARC) 85,

morphology 373

Disinfection 34, 35

140

pathogenesis 373

chemical methods

Duodenal ulcer 307, 638

see also Dermatomy-

39 –40

Dysentery 280, 287–289

coses

kinetics of pathogen

clinical picture 288

Desensitization 140

killing 35–36

diagnosis 288, 638

Deuteromycetes 348, 352

mechanisms of action

epidemiology 288 –289

Diagnosis see Laboratory

36 –37

prevention 289

diagnosis; specific infec-

physical methods of

therapy 288

tions

37–38

see also Shigella

Diaminobenzyl pyrimidine

heat 37–38

190

radiation 38

&E

Diaminopyrimidines 533

practical disinfection

Dicrocoelium

40 –41

dendriticum 543, 556,

Disposition 8, 11

E-selectin (ELAM) 529

557

DNA

Ear infections 658

diagnosis 641, 643

amplification techniques

Early antigen (EA) 424

Dientamoeba fragilis

216–217

Early summer menin-

504–505

bacterial DNA structure

goencephalitis (ESME) 607

Differential staining 148,

167–168

Ebola virus 471

211–212

cloning 178 –179

clinical picture 471

DiGeorge syndrome 140

modification 177–178

diagnosis 471, 650

Digestion 161

replication 168, 181

epidemiology 471

Digestive gland infections

topology 150

pathogenesis 471

641–643

transcription 168–169,

prevention 471

see also specific infections

181

Echinocandins 357

Dihydropropoxymethyl-

translation 169, 181

Echinococcus (echinococ-

guanosine (DHPG) 404

transposable elements

cosis) 565 –575, 634

Dilution coefficient 36

173

granulosus 565,

Dilution series tests 204

virulence regulation

566–571

Dinitrophenol (DNP) 140

mechanisms 18–19

clinical manifestations

Diphtheria 254, 257

DNA probes 216

568–571

clinical picture 256, 257

DNA tumor viruses 396

control 571

diagnosis 256–257, 631

DNA viruses 377–378,

diagnosis 571, 625,

epidemiology 257–258

412–434

643, 646

nasopharyngeal 257

double-stranded

epidemiology 568

prevention 258

413–434

hosts 566

therapy 257

replication 384–385,

life cycle 566–568

see also Corynebacterium

387

morphology 566, 569

diphtheriae

single-stranded

occurrence 566

Diphtheria toxin 16, 254,

412–413

prevention 571

256

see also specific viruses

therapy 571

detection 257

DNases 238

transmission 29

regulation 18–19

Domain 140

multilocularis 565,

Diphyllobothrium (diphyl-

Double diffusion techni-

571–574

lobothriosis) 561, 575–576

que 121–122

clinical manifestations

clinical manifestations

Doxycycline 194, 533

570, 574

576

Dracunculoidea 545

control 574

diagnosis 576, 640

Dracunculus medinensis

diagnosis 574, 625,

life cycle 576

(dracunculosis) 596

643, 646

occurrence 575 –576

diagnosis 653

distribution 572

prevention 576

Drug resistance

epidemiology

therapy 576

antimalarial drugs 532

573–574

Diplomonadea 477

resistance plasmids 167,

hosts 573

Diptera 606

168, 176, 177

life cycle 567, 573

Dirofilaria (dirofilariosis)

see also Antibiotic resis-

morphology 569, 572

605

tance

prevention 574

Enterococci E 673

therapy 574

localization 541

nosocomial infection

transmission 29

occurrence 541

343

oligarthrus 565, 575

symptoms 541

sakazakii 295

voegeli 565, 575

see also Microsporidia

Enterobacteriaceae 223,

Echinostomida 545

(microsporidiosis)

278 –282

Echovirus 436

Encephalomyelitis

antibiotic resistance 296

clinical syndromes 436

645 –646

antigen structure 281

diagnosis 653

Endemic occurrence 27

culture 279

Ecserohilum 369

Endocarditis 159, 242

definition 279

Effector molecules 170,

diagnosis 647

diagnosis

179

Endolimax nana 504–505

cardiovascular system

Ehrlichia (ehrlichiosis) 227,

Endometritis 636

647

330, 333

Endophthalmitis 365,

cutaneous infection

chaffeensis 227, 333

656 –657

651

diagnosis 649

Endospores 159–160

digestive glands 641,

epidemiology 333

Endotoxins 140, 156

642

ewingii 227, 333

Bordetella pertussis 315

eye infections 655,

human granulocytic

Enterobacteriaceae 282

656, 657

ehrlichiosis (HGE) 333

see also Lipopolysac-

muscle/joint infection

human monocytic ehrli-

charide

654

chiosis (HME) 333

Enoplida 545

nervous system 644,

sennetsu 333

Enoxacin 189

646

Ehrlichiosis see Ehrlichia

Entamebiosis see Amebo-

peritonitis 642, 643

(ehrlichiosis)

sis

respiratory tract 633

Eikenella corrodens 222,

Entamoeba

urogenital tract 635,

304

coli 505

636

Electron microscopy (EM)

diagnosis 503 –506, 625,

identification of 214

409

639

morphology 279

Electrophoresis

antibody assay 506

normal microbial flora

immunoelectrophoresis

coproantigen detec-

25

technique 122–123, 124

tion 506, 622

nosocomial infection

Western blotting 123,

coproscopic diagnosis

343

125

503

opportunistic 295 –296

Elephantiasis 590 –591

differential diagnosis

pathogenicity determi-

ELISA (enzyme-linked im-

504–506

nants 282

munosorbent assay)

stool specimen hand-

significance 279

128–129, 132, 140

ling 621

taxonomy 279

ELISPOT assay 131, 132, 140

dispar 499 –506

see also Enterobacter

Emmonsiella capsulata 358

hartmanni 504–505

Enterobius vermicularis

Empyema 634

histolytica 499–506

(enterobiosis) 544,

subdural 646

cysts 500

585 –586

Encephalitis 421, 428, 443,

diagnosis 503–506,

clinical manifestations

466

639, 642

586

California 461

epidemiology 502

diagnosis 586, 640

granulomatous amebic

life cycle 501

specimen handling

(GAE) 507

pathogenesis

622

Japanese B 443

500–502

epidemiology 585 –586

St. Louis 443

trophozoites 500

life cycle 585 –586

tickborne (TBE) 28, 443,

occurrence 499

morphology 585

607

see also Amebosis

occurrence 585

diagnosis 644, 645

Enteritis 289, 290, 291

pathogenesis 586

see also Ixodes

viral 439

prevention 586

Encephalitozoon 540

see also Yersinia entero-

therapy 586

cuniculi 541

colitica

Enterococci 220, 235, 236,

diagnosis 635

Enterobacter 223, 280

243–244

hellem 541

aerogenes 295

antibiotic resistance

intestinalis 538,

agglomerans 295

243–244

540 –541

cloace 295

diagnosis 635

Lancefield groups 235

Epidural abscess 646

enterotoxic (ETEC) 280,

normal microbial flora

Epiglottitis 631

293

25

Episome 179

extraintestinal infec-

nosocomial infection

Epitopes 44–45, 140

tions 292 –293

343

conformational (struc-

sepsis 293

Enterococcus

tural) 68

urinary tract infection

faecalis 220, 236, 243

sequential (linear) 68

292 –293

faecium 220, 236, 243

Epstein-Barr nuclear anti-

F-factor 176–177

Enterocolitis 638

gen (EBNA) 425

intestinal infections 292,

Enterocytozoon 539

Epstein-Barr virus 140,

638

bieneusi 538, 540

418, 424–425

morphology 292

diagnosis 540, 639

clinical picture 424

nosocomial infection

localization 540

diagnosis 424–425

343

occurrence 540

hematopoietic system

pathogenesis 292 –294

see also Microsporidia

648

prevention 294

(microsporidiosis)

nervous system 645

therapy 294

Enterotoxins 15, 232, 282,

respiratory tract 631,

uropathogenic (UPEC)

293

632

293

cholera toxin 16,

epidemiology 425

verotoxin-producing

297– 298

pathogenesis 424

(VTEC) 294

mechanism of action

therapy 425

Ethambutol 191

298

Erypselas 651

Ethanol 39

Enterovirus 435–436

Erysipeloid 252, 253

Ethylene oxide 39

Enteroviruses 434,

diagnosis 651

Eubacterium sp. 261

435–437

Erysipelothrix rhusio-

Euglenozoa 477

clinical pictures 436

pathiae 221, 252, 253

Eukaryotes 4–5, 6

diagnosis 436

diagnosis 651

characteristics of 6

cardiovascular system

Erythema infectiousum

Exanthema

647

412–413

measles 466

eye infections 655

diagnosis 650

scabies 611

gastrointestinal tract

Erythema migrans 326,

subitum 425

638

327

diagnosis 650

nervous system 644,

diagnosis 651

vesicular 420

645

Erythroblastosis fetalis 112

Exfoliatins 232

respiratory tract 631,

Erythromycin 191

Exoenzyme S 309

633

Erythrovirus 382

Exon 140

epidemiology 436 –437

Escape mutants 430

Exophiala werneckii 374

pathogenesis 436

Escherichia coli 223,

Exotoxins 15

pathogens 435–436

280 –281, 292 – 294

Bordetella pertussis 315

prevention 437

antigen structure 292

Enterobacteriaceae 282

env gene 449, 450

characteristics 292

exotoxin A 309

Envelope, viral 377, 378

clinical pictures

pyrogenic streptococcal

Enzyme immunoassay

292 –294

exotoxins (PSE) 238

(EIA) 128 –129, 409

diagnosis 294

Exposure prophylaxis 31,

Eotaxin 83, 140

digestive glands 641,

402

Epicillin 193

642

Eye infections 416,

Epidemic 27

gastrointestinal tract

655 –657

Epidemic myalgia 653

638

conjunctivitis 303, 416,

Epidemiology 25 –34

nervous system 644

655

sources of infection 30

urogenital tract 635

inclusion 336, 339

terminology 26, 27

enteroaggregative (EAg-

swimming-pool 336,

transmission 26 –30

gEC) 280, 294

339

see also Infectious dis-

enterohemorrhagic

cysticercosis 564, 657

eases

(EHEC) 280, 294

endophthalmitis 365,

Epidermophyton spp. 355,

enteroinvasive (EIEC)

656 –657

373

280, 293

keratitis 428, 656

floccosum 374

enteropathogenic

scleritis 655

see also Dermatophytes

(EPEC) 280, 293

toxoplasmosis 513